

研究成果の刊行に関する一覧



Nakashima M, Ode H, Kawamura T, Kitamura S, Naganawa Y, Awazu H, Tsuzuki S, Matsuoka K, Nemoto M, Hachiya A, Sugiura W, Yokomaku Y, Watanabe N, Iwatani Y. 2016. Structural insights into HIV-1 Vif-APOBEC3F interaction. *J Virol.* 90:1034-47. 2015.

Hosaka M, Fujisaki S, Masakane A, Hattori J, Shiino T, Gatanaga H, Shigemi U, Okazaki R, Hachiya A, Matsuda M, Ibe S, Iwatani Y, Yokomaku Y, Sugiura W; Japanese Drug Resistance HIV-1 Surveillance Network Team. HIV-1 CRF01_AE and Subtype B Transmission Networks Crossover: A New AE/B Recombinant Identified in Japan. *AIDS Res Hum Retroviruses.* 2015.

Ogawa S, Hachiya A, Hosaka M, Matsuda M, Ode H, Shigemi U, Okazaki R, Sadamasu K, Nagashima M, Toyokawa T, Tateyama M, Tanaka Y, Sugiura W, Yokomaku Y, Iwatani Y. A Novel Drug-Resistant HIV-1 Circulating Recombinant Form CRF76_01B Identified by Near Full-Length Genome Analysis. *AIDS Res Hum Retroviruses.* 2015.

Hachiya A, Ode H, Matsuda M, Kito Y, Shigemi U, Matsuoka K, Imamura J, Yokomaku Y, Iwatani Y, Sugiura W. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance. *Antiviral Res.* 119:84-8. 2015.

Ode H, Matsuda M, azuhiro Matsuoka K, Hachiya A, Hattori J, Kito Y, Yokomaku Y, Iwatani Y, Sugiura W. Quasispecies Analyses of the HIV-1 Near-full-length Genome With Illumina MiSeq Front Microbiol. 6:1258. 2015.

Tsuzuki Y, Watanabe T, Iio E, Fujisaki S, Ibe S, Kani S, Hamada-Tsutsumi S, Yokomaku Y, Iwatani Y, Sugiura W, Okuse C, Okumura A, Sato Y, Tanaka Y. Evidence for Widespread of Hepatitis B Genotype G/A2 Recombination Virus Japan. *Hepatology Research.* 2015.

Nakashima M, Ode H, Suzuki K, Fujino M, Maejima M, Kimura Y, Masaoka T, Hattori J, Matsuda M, Hachiya A, Yokomaku Y, Suzuki A, Watanabe N, Sugiura W and Iwatani Y. Unique Flap Conformation in an HIV-1 Protease with High-level Darunavir Resistance. *Front Microbiol.* 7:61. 2016 Feb 3.

Hirashima N, Iwase H, Shimada M, Imamura J, Sugiura W, Yokomaku Y, Watanabe T. An Hepatitis C Virus (HCV)/HIV Co-Infected Patient who Developed Severe Hepatitis during Chronic HCV Infection: Sustained Viral Response with Simeprevir Plus Peginterferon-Alpha and Ribavirin. *Intern Med.* 54(17):2173-7. 2015.

Iwamoto A, Taira R, Yokomaku Y, Koibuchi T, Rahman M, Izumi Y, Tadokoro K. The HIV care cascade: Japanese perspectives. *PLOS ONE.* Epub 2017 Mar 20.

Sawada I, Tsuchiya N, D Cuong, P Thuy, R Archawin, A Marissa, L Katerina, Yokomaku Y, P Panita, Ariyoshi K; Regional Differences in the Prevalence of Major Opportunistic Infections among Antiretroviral-Naïve HIV Patients in Japan, Northern Thailand, Northern Vietnam, and the Philippines by Gangcuangco, Louie Mar. *American Journal of Tropical Medicine & Hygiene.* 2017 Feb. [Epub ahead of print]

Hirashima N, Iwase H, Shimada M, Ryuge N, Imamura J, Ikeda H, Tanaka Y, Matsumoto N, Okuse C, Itoh F, Yokomaku Y, Watanabe T. Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir. *Clin J Gastroenterol.* 2016 Oct 20. [Epub ahead of print]

Pett SL, Amin J, Horban A, et al.; Maraviroc Switch (MARCH) Study Group. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study. *Clin Infect Dis*. 63(1):122-32. doi: 10.1093/cid/ciw207. Epub 2016 Apr 5.

Miyazaki N, Sugiura W, Gatanaga H, Watanabe D, Yamamoto Y, Yokomaku Y, Yoshimura K, Matsushita S; Japanese HIV-MDR Study Group. High antiretroviral coverage and viral suppression prevalence in Japan: an excellent profile for downstream HIV care spectrum. *Jpn J Infect Dis*. 2016. [Epub ahead of print]

Kaku Y, Kodama S, Higuchi M, Nakamura A, Nakamura M, Kaieda T, Takahama S, Minami R, Miyamura T, Suematsu E, Yamamoto M. Corticoid therapy for overlapping syndromes in an HIV-positive patient. *Intern Med*. 54(2):223-30, 2015.

Minami R, Takahama S, Kaku Y, Yamamoto M. Addition of maraviroc to antiretroviral therapy decreased interferon- γ mRNA in the CD4+ T cells of patients with suboptimal CD4+ T-cell recovery. *J Infect Chemother*. 2016 Oct 8. pii: S1341-321X (16)30181-7.

Mizushima D, Nishijima T, Yashiro S, Teruya K, Kikuchi Y, Katai N, Oka S, and Gatanaga H. Diagnostic utility of quantitative plasma cytomegalovirus DNA PCR for cytomegalovirus end-organ diseases in patients with HIV-1 infection. *JAIDS*. 68(2):140-146, 2015.

Ogishi M, Yotsuyanagi H, Tsutsumi T, Gatanaga H, Ode H, Sugiura W, Moriya K, Oka S, Kimura S, and Koike K. Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: Comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfecting hemophiliacs and HCV monoinfected patients in Japan. *PLOS One*. 10(3):e0119145, 2015.

Murakoshi H, Akahoshi T, Koyanagi M, Chikata T, Naruto T, Maruyama R, Tamura Y, Gatanaga H, Oka S and Takiguchi M. Clinical control of HIV-1 by cytotoxic T cells specific for multiple conserved epitopes. *J Virol*. 89(10):5330-5339, 2015.

Sawada I, Tanuma J, Do CD, Doan TT, Luu QP, Nguyen LAT, Vu TVT, Nguyen TQ, Tsuchiya N, Shiino T, Yoshida LM, Pham TTT, Ariyoshi K, and Oka S. High Proportion of HIV Serodiscordance among HIV-affected Married Couples in Northern Vietnam. *PLOS One*. 10(4):e0125299, 2015.

Kuse N, Rahman MA, Murakoshi H, Chikata T, Giang TV, Kinh NV, Gatanaga H, Oka S, and Takiguchi M. Different effects of NNRTI-resistant mutations on CTL recognition between HIV-1 subtype B and subtype A/E infections. *J Virol*. 89(14):7363-7372, 2015.

Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczek D, Molia JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S, for the GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomized, double-blind, phase 3, non-inferiority trials. *Lancet*. 85(9987):2606-2615, 2015.

Tanizaki R, Nishijima T, Aoki T, Teruya K, Kikuchi Y, Oka S, and Gatanaga H. High-dose oral Amoxicillin plus probenecid is highly effective for syphilis in patients with HIV infection. *Clin Infect Dis*. 61(2):177-183, 2015.

Kinai E, Gatanaga H, Kikuchi Y, Oka S, Kato S. Ultrasensitive method to quantify intracellular zidovudine mono-, di- and triphosphate concentrations in peripheral blood mononuclear cells by liquid chromatography-tandem mass spectrometry. *J Mass Spectrom*. 50(6):783-791, 2015.

Nishijima T, Yashiro S, Teruya K, Kikuchi Y, Katai N, Oka S, Gatanaga H. Routine eye screening by an ophthalmologist is clinically useful for HIV-1-infected patients with CD4 count less than 200 / μ L. *PLOS One*. 10(9):e0136747, 2015.

Nagata N, Watanabe K, Nishijima T, Tadokoro K, Watanabe K, Shimbo T, Niikura R, Sekine K, Akiyama J, Gatanaga H, Teruya K, Kikuchi Y, Uemura N, and Oka S. Prevalence of anal papillomavirus infection and risk factors among HIV- positive patients in Tokyo, Japan. *PLOS One*. 10(9):e0137434, 2015.

Hashimoto M, Nasser H, Bhuyan F, Kuse N, Satou Y, Harada S, Yoshimura K, Sakuragi J, Monde K, Maeda Y, Welbourn S, Strebel K, Abd EW, Wahab E, Miyazaki M, Hattori S, Chutiwitoonchai N, Hiyoshi M, Oka S, Takiguchi M, and Suzu S. Fibrocytes differ from macrophages but can be infected with HIV-1. *J Immune*. 95(9):4341-4350, 2015.

Shibata S, Nishijima T, Aoki T, Tanabe Y, Teruya K, Kikuchi Y, Kikuchi T, Oka S, and Gatanaga H. A 21-day of adjunctive corticosteroid use is not necessary for HIV-1-infected pneumocystis pneumonia with moderate severity. *PLOS One*. 10(9):e0138926, 2015.

Matsumoto S, Tanuma J, Mizushima D, Thi CN, Pham TTT, Cuong DD, Tuan Q, Dung T, Dung HTN, Tien L, Kinh V, and Oka S. High treatment retention rate in HIV-infected patients on antiretroviral therapy at two large HIV clinics in Hanoi, Vietnam. *PLOS One*. 10(9):e0139594, 2015.

Nishijima T, Hayashida T, Kurosawa T, Tanaka N, Tsuchiya K, Oka S, Gatanaga H. Drug transporter genetic variants are not associated with TDF-related renal dysfunction in patients with HIV-1 infection: a pharmacogenetic study. *PLOS One*. 10(11):e0141931, 2015.

Nishijima T, Takano M, Koyama M, Sugino Y, Ogane M, Ikeda K, Kikuchi Y, Oka S, and Gatanaga H. What triggers a diagnosis of HIV infection in Tokyo metropolitan area? Implications for preventing spread of HIV epidemics in Japan. *PLOS One*. 10(11):e0143874, 2015.

Takahashi Y, Nagata N, Shimbo T, Nishijima T, Watanabe K, Aoki T, Sekine K, Okubo H, Watanabe K, Sakurai T, Yokoi C, Mimori A, Oka S, Uemura N, and Akiyama J. Upper Gastrointestinal Symptoms Predictive of Candida Esophagitis and Erosive Esophagitis in HIV and Non-HIV Patients: An Endoscopy-Based Cross-Sectional Study of 6,011 Patients. *Medicine(Baltimore)*. 94(47):e2138, 2015.

Tsuchiya K, Hayashida T, Hamada A, Oka S, and Gatanaga H. High peak level of plasma raltegravir concentration in patients with ABCB1 and ABCG2 genetic variants. *J AIDS* (Brief Report)72: 11-14, 2016.

Ondondo B, Clutton G, Abdul-Jawad S, Wee E, McMichael AJ, Murakoshi H, Gatanaga H, Oka S, Takiguchi M, Korber B and Hanke T. Novel conserved-region T-cell mosaic vaccine with high global HIV coverage is recognized by protective responses in untreated infection. *Molecular Therapy* 24(4):832-842, 2016.

Tran GV, Chikata T, Carlson J, Murakoshi H, Nguyen DH, Tamura Y, Akahoshi T, Kuse N, Sakai K, Koyanagi M, Sakai S, Cobarrubias K, Nguyen DT, Dang BT, Nguyen HTN, Nguyen TV, Oka S, Brumme Z, Nguyen KV, and Takiguchi M. A strong association of HLA-associated Pol and Gag mutations with clinical parameters in HIV-1 subtype A/E infection. *AIDS* 30(5):681-689, 2016.

Boonchawalit S, Harada S, Shirai N, Gatanaga H, Oka S, Matsushita S, Yoshimura K. Impact of maraviroc-resistant mutation M434I in the C4 region of gp120 on sensitivity to antibody-mediated neutralization. *Jap J Infect Dis* 69: 236-243, 2016.

Nishijima T, Kurosawa T, Tanaka N, Kawasaki Y, Kikuchi Y, Oka S, and Gatanaga H. Urinary β 2 microglobulin can predict TDF-related renal dysfunction in HIV-1-infected patients who initiate TDF-containing antiretroviral therapy. *AIDS* 30 (10):1563-1571, 2016.

Kinai E, Kato S, Hosokawa S, Tanaka M, Nakanishi M, Sadatsuki M, Tanuma J, Gatanaga H, Yano T, Kikuchi Y, Hanh MTH, Loan NT, Lam NV, Ha DQ, Kinh NV, Tien NV, Liem NT, and Oka S. High plasma concentration of zidovudine (AZT) is not parallel with intracellular concentration of AZT-triphosphate in infants during prevention of mother-to-child HIV-1 transmission. *J AIDS* 72(3):246-253, 2016.

Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, Tashima K, Arribas JR, Rashbaum B, Cheret A, Brunetta J, Mussini C, Tebas P, Sax PE, Cheng A, Zhong L, Callebaut C, Das M, Fordyce M; GS-US-292-01040111 Study Team. A randomized, double-blind comparison of tenofovir alafenamide (TAF) vs. tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 96 results. *JAIDS* 72(1):58-64, 2016.

Tanuma J, Lee KH, Haneuse S, Matsumoto S, Dung NT, Dung NTH, Cuong DD, Thuy PTT, Kinh NV, and Oka S. Incidence of AIDS-Defining Opportunistic Infections and Mortality during Antiretroviral Therapy in a Cohort of Adult HIV-Infected Individuals in Hanoi 2007-2014. *PLOS One* 11(3): e015078, 2016.

Chen M, Wong WW, Law M, Kiertiburanakul S, Yunihastuti E, Merati TP, Lim PL, Chaiwarith R, Phanuphak P, Lee MP, Kumarasamy N, Saphonn V, Ditangco R, Sim B, Nguyen KV, Pujari S, Kamarulzaman A, Zhang F, Pham TT, Choi JY, Oka S, Kantipong P, Mustafa M, Ratanasuwan W, Durier N, Chen YMA. Hepatitis B and C co-infection in HIV patients from the Treat Asia HIV Observational Database: Analysis of Risk Factors and Survival. *PLOS One* 11(3): e0150512, 2016.

Kobayashi T, Nishijima T, Teruya K, Kikuchi Y, Oka S, and Gatanaga H. High mortality of disseminated non-tuberculous mycobacterial infection in HIV-infected patients in the antiretroviral therapy era. *PLOS One* 11(3): e0151682, 2016.

Do TC, Boettiger D, Law M, Pujari S, Zhang F, Chaiwarith R, Kiertiburanakul S, Lee MP, Ditangco R, Wong WW, Nguyen KV, Merati TP, Pham TT, Kamarulzaman A, Oka S, Yunihastuti E, Kumarasamy N, Kantipong P, Choi JY, Ng OT, Durier N, Ruxrungtham K. Smoking and projected cardiovascular risk in an HIV-positive Asian regional cohort. *HIV Med* 17(7):542-549, 2016.

Jiamsakul A, Kerr SJ, Ng OT, Lee MP, Chaiwarith R, Yunihastuti E, Van Nguyen K, Pham TT, Kiertiburanakul S, Ditangco R, Saphonn V, Sim BL, Merati TP, Wong W, Kantipong P, Zhang F, Choi JY, Pujari S, Kamarulzaman A, Oka S, Mustafa M, Ratanasuwan W, Petersen B, Law M, Kumarasamy N; TREAT Asia HIV Observational Database (TAHOD). Effects of unplanned treatment interruptions on HIV treatment failure-results from TAHOD. *Trop Med Int Health*. 21(5):662-674, 2016.

Borges AH, Lundh A, Tendal B, Bartlett JA, Clumeck N, Costagliola D, Daar ES, Echeverría P, Gisslén M, Huedo-Medina TB, Hughes MD, Hullsiek KH, Khabo P, Komati S, Kumar P, Lockman S, nMacArthur RD, Maggiolo F, Matteelli A, Miro JM, Oka S, Petoumenos K, Puls RL, Riddler SA, Sax PE, Sierra-Madero J, Torti C and Lundgren JD. Non-nucleoside reverse transcriptase inhibitor-versus ritonavir-boosted protease inhibitor-based regimens for initial treatment of HIV infection: a systematic review and meta-analysis of randomised trials. *Clin Infect Dis* 63(2):268-80, 2016.

Sun X, Shi Yi, Akahoshi T, Fujiwara M, Gatanaga H, Schonbach C, Kuse N, Appay V, Gao GF, Oka S, and Takiguchi M. Effects of single escape mutation on T cell and HIV-1 co-adaptation. *Cell Reports* 15(10): 2279-2291, 2016.

Gallant J, Brunetta J, Crofoot G, Benson P, Mills A, Brinson C, Oka S, Cheng A, Garner W, Fordyce M, Das M, McCallister S; GS-US-292-1249 Study Investigators. Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) in HIV-1/Hepatitis B Coinfected Adults. *JAIDS* (Brief Report) 73 (3); 294-298, 2016.

Yanagawa Y, Nagata N, Watanabe K, Tsukada K, Teruya K, Kikuchi Y, Gatanaga H, Akiyama J, Uemura N, and Oka S. Increases in *Entamoeba histolytica*-antibody-positive rates in HIV-infected and non-infected patients in Japan: A 10-year hospital-based study of 3514 patients. *Am J Trop Med Hyg* 95 (3); 604-609, 2016.

Tsuboi M, Nishijima T, Yashiro S, Teruya K, Kikuchi Y, Katai N, Oka S, Gatanaga H. Prognosis of ocular syphilis in patients infected with HIV in the antiretroviral therapy era. *Sex Transm Infect* 92 (8); 605-610, 2016.

Hayashida T, Hachiya A, Ode H, Nishijima T, Tsuchiya K, Sugiura W, Takiguchi M, Oka S, and Gatanaga H. Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations. *J Antimicrob Chemother* 71(10); 2760-2766, 2016.

Lin Z, Kuroki K, Kuse N, Sun X, Akahoshi T, Qi Y, Chikata T, Naruto T, Koyanagi M, Murakoshi H, Gatanaga H, Oka S, Carrington M, Maenaka K, and Takiguchi M. Control of HIV-1 replication by NK cells via reduced interaction between KIR2DL2 and HLA-C*12:02/C*14:03. *Cell Reports* 17(9): 2210-2220, 2016.

Tsuboi M, Nishijima T, Teruya K, Kikuchi Y, Gatanaga H, and Oka S. Cerebral syphilitic gumma which developed within 5 months of syphilis infection in a HIV-infected patient. *Emerg Infect Dis (letter)* 22(10): 1846-1848, 2016.

Ahn JY, Boettiger D, Kiertiburanakul S, Merati TP, Huy BV, Wong WW, Ditangco R, Lee MP, Oka S, Durier N, Choi JY; Treat Asia HIV Observational Database. Incidence of syphilis seroconversion among HIV-infected persons in Asia: results from the TREAT Asia HIV Observational Database. *J Int AIDS Soc* 19(1): 20965, 2016.

Ku NS, Jiamsakul A, Ng OT, Yunihastuti E, Cuong DD, Lee MP, Sim BL, Phanuphak P, Wong WW, Kamarulzaman A, Zhang F, Pujari S, Chaiwarith R, Oka S, Mustafa M, Kumarasamy N, Van Nguyen K, Ditangco R, Kiertiburanakul S, Merati TP, Durier N, Choi JY; TREAT Asia HIV Observational Databases (TAHOD).

Elevated CD8 T-cell counts and virological failure in HIV-infected patients after combination antiretroviral therapy. *Medicine (Baltimore)* 95(32): e4570, 2016.

Nishijima T, Teruya K, Sgubata S, Yanagawa Y, Kobayashi T, Mizushima D, Aoki T, Kinai E, Yazaki H, Tsukada K, Genka I, Kikuchi Y, Oka S, and Gatanaga H. Incidence and risk factors for incident syphilis among HIV-1-infected men who have sex with men in a large urban HIV clinic in Tokyo. *PLOS One* 11 (12): e0168642, 2016.

Kamori D, Hasan Z, Ohashi J, Kawana-Tachikawa A, Gatanaga H, Oka S, and Ueno T. Identification of two unique naturally occurring Vpr sequence polymorphisms associated with clinical parameters in HIV-1 chronic infection. *J Med Virol* 89(1): 123-129, 2017.

Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, Inoue T, Enomoto N, Shirasaki T, Honda M, Kaneko S, Gatanaga H, Oka S, Kawamura Y, Dohi T, Shuno Y, Yano H, and Mizokami M. Induction of IFN- λ 3 as an additional effect of nucleotide, not nucleoside, analogs: a new potential target for hepatitis B virus infection. *Gut* 2016 Oct 27 [Epub ahead of print]

Kobayashi T, Watanabe K, Yano H, Murata Y, Nakada-Tsukui K, Yagita K, Nozaki T, Kaku M, Tsukada K, Gatanaga H, Kikuchi Y, and Oka S. Underestimated Amoebic Appendicitis among HIV-1-infected Individuals in Japan. *J Clin Microbiol* 2016 Nov 9. [Epub ahead of print]

Hayato Murakoshi, Madoka Koyanagi, Takayuki Chikata, Mohammad Arif Rahman, Nozomi Kuse, Keiko Sakai, Hiroyuki Gatanaga, Shinichi Oka, and Takiguchi M. Accumulation of Pol mutations selected by HLA-B*52:01-C*12:02 protective haplotype-restricted CTLs causes low plasma viral load due to low viral fitness of mutant viruses. *J Virol* 2016 Nov 30. [Epub ahead of print]

Hibino A, Kondo H, Masaki H, Tanabe Y, Sato I, Takemae N, Saito T, Zaraket H, Saito R.: Community- and hospital-acquired infections with oseltamivir and peramivir-resistant influenza A (H1N1)pdm09 viruses during the 2015-2016 season in Japan. *Virus Genes*. 2016 Oct 6.

Munehisa Fukusumi, Bin Chang, Yoshinari Tanabe, Kengo Oshima, Takaya Maruyama, Hiroshi Watanabe, Koji Kuronuma, Kei Kasahara, Hiroaki Takeda, Junichiro Nishi, Jiro Fujita, Tetsuya Kubota, Tomimasa Sunagawa, Tamano Matsui, Kazunori Oishi. the Adult IPD Study Group : Invasive pneumococcal disease among adults in Japan, April 2013 to March 2015: disease characteristics and serotype distribution. *BMC Infectious Diseases* 17:2, 2017

Yamada E, Ritsuo Takagi, Yoshinari Tanabe, Hiroshi Fujiwara, Naoki Hasegawa, Shingo Kato: Plasma and saliva concentrations of abacavir, tenofovir, darunavir and raltegravir in HIV-1-infected patients. *International Journal of Clinical Pharmacology and Therapeutics* (in press)

Niwa T, Watanabe T, Goto T, Ohta H, Nakayama A, Suzuki K, Shinoda Y, Tsuchiya M, Yasuda K, Murakami N, Itoh Y. Daily Review of Antimicrobial Use Facilitates the Early Optimization of Antimicrobial Therapy and Improves Clinical Outcomes of Patients with Bloodstream Infections. *Biol Pharm Bull*. 39(5): 721-7, 2016.

Muraki Y, Yagi T, Tsuji Y, Nishimura N, Tanabe M, Niwa T, Watanabe T, Fujimoto S, Takayama K, Murakami N, Okuda M. Japanese antimicrobial consumption surveillance: First report on oral and parenteral antimicrobial consumption in Japan (2009–2013). *J Glob Antimicrob Resist*. 7:19-23, 2016.

Yagura H, Watanabe D, Ashida M, Kushida H, Hirota K, Ikuma M, Ogawa Y, Yajima K, Kasai D, Nishida Y, Uehira T, Yoshino M, Shirasaka T. Correlation between UGT1A1 polymorphisms and raltegravir plasma trough concentrations in Japanese HIV-1-infected patients. *J Infect Chemother*. 21(10):713-7, 2015 Oct. Epub 2015 Jul 6.

Watanabe D, Suzuki S, Ashida M, Shimoji Y, Hirota K, Ogawa Y, Yajima K, Kasai D, Nishida Y, Uehira T, Shirasaka T. Disease progression of HIV-1 infection in symptomatic and asymptomatic seroconverters in Osaka, Japan: a retrospective observational study. *AIDS Res Ther*. 12:19. 2015.

Koizumi Y, Uehira T, Ota Y, Ogawa Y, Yajima K, Tanuma J, Yotsumoto M, Hagiwara S, Ikegaya S, Watanabe D, Minamiguchi H, Hodohara K, Murotani K, Mikamo H, Wada H, Ajisawa A, Shirasaka T, Nagai H, Kodama Y, Hishima T, Mochizuki M, Katano H, Okada S. Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases. *Int J Hematol*. 2016 Sep 7. [Epub ahead of print]

Akita T, Tanaka J, Ohisa M, Sugiyama A, Nishida K, Inoue S, Shirasaka T. Predicting future blood supply and demand in Japan with a Markov model: application to the sex- and age-specific probability of blood donation. *Transfusion*. 2016 Sep 5. doi: 10.1111/trf.13780. [Epub ahead of print]

Ikuma M, Watanabe D, Yagura H, Ashida M, Takahashi M, Shibata M, Asaoka T, Yoshino M, Uehira T, Sugiura W, Shirasaka T. Therapeutic Drug Monitoring of Anti-human Immunodeficiency Virus Drugs in a Patient with Short Bowel Syndrome. *Intern Med*. 2016;55(20):3059-3063. Epub 2016 Oct 15.

Honda M, Ito M, Tierney L et al. Reduction of behavioral psychological symptoms of dementia by multimodal comprehensive care for vulnerable geriatric patients in an acute care hospital. *Case Reports in Medicine*. 2016.

Suzuki A, Uehara Y, Saita M, Inui A, Isonuma H, Naito T. Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naïve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot Analysis. *Jpn J Infect Dis*. 69(1):33-8, 2016.

Liao CW, Fu CJ, Kao CY, Lee YL, Chen PC, Chuang TW, Naito T, Chou CM, Huang YC, Bonfim I, Fan CK. Prevalence of intestinal parasitic infections among school children in capital areas of the Democratic Republic of São Tomé and Príncipe, West Africa. *Afr Health Sci*. 2016;16(3):690-697.

Fukui S, Uehara Y, Fujibayashi K, Takahashi O, Hisaoka T, Naito T. Bacteraemia predictive factors among general medical inpatients: a retrospective cross-sectional survey in a Japanese university hospital. *BMJ Open*. 2016;6(7):e010527.

Naito T. Should Inflammatory Markers Be Used in the Diagnosis of a Fever of Unknown Origin? *Intern Med*. 2016;55(10):1407.

Naito T. Clinical Approach to Febrile Patients. *Juntendo Medical Journal*. 2016;3:224-227.

Masaki Hara, Naoki Yanagisawa, Akihito Ohta, Kumiko Momoki, Ken Tsuchiya, Kosaku Nitta, Minoru Ando. Increased non-HDL-C level linked with a rapid rate of renal function decline in HIV-infected patients. *Clin Exp Nephrol*. DOI 10.1007/s10157-016-1281-9

重見 麗、蜂谷敦子、松田昌和、岡崎玲子、小川慎太郎、伊藤恭子、健山正男、今村顕史、柳澤邦雄、矢野邦夫、藤井輝久、上田敦久、今村淳治、渡邊綱正、田中靖人、横幕能行、杉浦 互、岩谷靖雅. HIV-1 感染急性期におけるサイトカインのプロファイル解析. *日本エイズ学会誌*. 18(2):154-162, 2016.

- 松岡亜由子、森 祐子、石原真理、羽柴知恵子、今村淳治、中畑征史、横幕能行. 治療を拒否して対応に難渋したニューモシスチス肺炎発症AIDSの1例. *日本エイズ学会誌*. 18(2):136-141, 2016.
- 森 祐子、中畑征史、羽柴知恵子、横幕能行. HIV感染症罹患に伴う喪失体験から抑うつ症状を呈した1例. *日本エイズ学会誌*. 18(2):125-129, 2016.
- 須貝 恵、吉用 緑、センテノ田村恵子、鈴木智子、辻 典子、井内亜紀子、濱本京子、田邊嘉也、伊藤俊広. 診療案内からみる拠点病院の現状. *日本エイズ学会誌*. 17(3):184-186, 2015.
- 金子典代、塩野徳史、内海 眞、健山政男、鬼塚哲郎、伊藤俊広、市川誠一. 成人男性のHIV検査受検、知識、HIV関連情報入手状況、HIV陽性者の身近さの実態—2009年調査と2012年調査の比較—. *日本エイズ学会誌*. 2016、受理
- 須貝 恵、吉用 緑、センテノ田村恵子、鈴木智子、辻 典子、築山亜紀子、濱本京子、田邊嘉也、伊藤俊広. 拠点病院診療案内2014年度版からみる拠点病院・中核拠点病院の現状. *日本エイズ学会誌*. 18(3):253-255, 2016
- 高濱宗一郎、郭 悠、中嶋恵理子、南 留美、山本政弘. HIV感染症合併ニューモシスチス肺炎の治療効果判定におけるガリウムシンチの有用性と治療期間の検討. *感染症学会雑誌*. 89(2):254-258, 2015.
- 嶋根卓也、今村顕史、池田和子、山本政弘、辻 麻理子、長與由紀子、大久保 猛、太田実男、神田博之、岡崎重人、大江昌夫、松本俊彦. DAST-20日本語版の信頼性・妥当性の検討. *日本アルコール・薬物医学会雑誌*. 50(6):310-324, 2015.
- 山本政弘. HIV感染症の課題. *透析療法ネクストXIX* (HIV診療と透析医療の関わり) . 83-89,2015.8
- 山本政弘. HIV感染症の現在. *Visual Dermatology* 【ここまでわかった皮膚科領域のウイルス性疾患—ヘルペスから新興ウイルス感染症まで】 (Part2.)ウイルス感染症の現在. 14(8), 936-939, 2015.8
- 南 留美、山本政弘. 感染症診断の新たなツール病原体検出の実際. HIVの遺伝子分析における臨床的有用性 (解説/特集) *化学療法の領域*. (0913-2384)2015年31巻増刊S-1 Page157(1035)-164(1042) 2015.4
- 山本政弘. HIV感染者の妊娠と出産. *内科* 116,5, 847-850, 2015.11
- 阪木淳子、辻 麻理子、首藤美奈子、山地由恵、犬丸真司、郭 悠、高濱宗一郎、南 留美、山本政弘. 【困難事例とカウンセリング】 内服困難事例へのチーム支援におけるカウンセラーの役割. *日本エイズ学会誌*. (1344-9478)18巻2号 Page120-124 2016/05
- 山本政弘. 【HIV感染症の流行はまだ続いている】 HIV感染症と他の性感染症の重複感染. *化学療法の領域*. (0913-2384)32巻5号 Page973-978 2016/04
- 遠藤知之: 「HIV感染症」, 危惧する感染症—院内感染防止対策—, *Surgery Frontier*, メディカルレビュー社, 22(3):17-23, 2015.
- 遠藤知之: 「HIVに求められる感染対策」, すべての内科医のためのHIV感染症—長期管理の時台—, 内科, 南江堂, 116: 815-819, 2015.
- 遠藤知之. 「医療現場における曝露後予防」、エイズの臨床 アップデート、アレルギー・免疫. *医薬ジャーナル社*. 23 (5): 90-95, 2016

田邊嘉也:「HIV/AIDSの最近の診断、治療法と課題について」. **新潟県医師会報**. 789:P48-, 2015.

須貝 恵、田邊嘉也、他：診療案内からみる拠点病院の現状. **日本エイズ学会誌**. 17:184-186, 2015.

永井孝宏、児玉泰光、黒川 亮、西川 敦、山田瑛子、田邊嘉也、高木律男. HIV感染者における歯科観血的処置の臨床的検討. **新潟歯学会誌**. 46: 13-19, 2016

白阪琢磨. HIV感染症/エイズ. **公衆衛生看護学 第2版** 中央法規出版株式会社. 2016年12月.

白阪琢磨. 自覚症状のないうちに進行するHIV感染—感染後10年ほど潜伏し、次第に免疫力が弱まるとエイズを発症します. **中学・高校保健ニュース**. 1, 2016年11月.

白阪琢磨. 患者を生きる. 3191 感染症 HIV5 情報編. **朝日新聞12版**. 33, 2016年12月.

白阪琢磨. HIV感染防止作戦 若い女性への拡がり懸念. **朝日新聞4版**. 13, 2016年12月.

白阪琢磨. 抗HIV薬. 治療薬ハンドブック2017. **株式会社じほう**. 2017年1月.

齊藤誠司、城下由衣、小川良子、池田有里、浅井いづみ、喜花伸子、金崎慶大、藤井健司、藤田啓子、畝井浩子、山崎尚也、藤井輝久、高田昇. 診断の遅れからエイズ指標疾患を発症し、輸血前感染症検査にて診断にいたった中高年HIV感染者の3症例. **日本エイズ学会誌**. 2016;18(3):224-229

山崎尚也、藤井輝久、齊藤誠司、浅井いづみ、小川良子、金崎慶大、喜花伸子、池田有里、木下一枝、藤井健司、藤田啓子、畝井浩子、高田昇. 広島大学病院におけるHIV感染者の骨代謝異常症の現状と原因の検討. **日本エイズ学会誌**. 2017;19(1):32-36

宇佐美雄司: まだまだ誤解されている AIDS と歯科医療の関係. **日本歯科医師会雑誌**. 68:311-318, 2015.

前田憲昭、北川善政、長坂 浩、高木律男、大多和由美、宇佐美雄司、有家 巧、宮田 勝、柴 秀樹、吉川博政、秋野憲一、溝部潤子、池田正一: HIV感染者歯科診療ネットワーク構築と課題. **日本エイズ学会誌**. 17:179-183, 2015.

宇佐美雄司、北川善政、長坂 浩、高木律男、宮田 勝、有家 巧、柴 秀樹、吉川博政、大多和由美、丸岡豊: HIV感染者の歯科治療ガイドブック. 歯科の医療体制整備に関する研究. 2016.

宇佐美雄司: 口から発見するエイズ. **8020会誌** Vol 15 99-101 2016年2月

宇佐美雄司、北川善政、長坂 浩、高木律男、宮田 勝、有家 巧、吉川博政. 本邦におけるHIV感染者の歯科医療体制構築について. HIV感染者の歯科診療ネットワークの構築. **日本口腔外科学会**. P15-17. 2016年3月

宮田 勝、高木純一郎、名倉 功、宇佐美雄司、坂下英明. 石川県におけるHIV感染症歯科診療ネットワーク構築について. HIV感染者の歯科診療ネットワークの構築. **日本口腔外科学会**. P28-31. 2016年3月

宇佐美雄司、菱田純代、総山貴子、荒川美貴子、石原美信. 愛知県におけるHIV感染者の歯科医療体制構築の取組み. HIV感染者の歯科診療ネットワークの構築. **日本口腔外科学会**. P33-35. 2016年3月

宇佐美雄司. 歯科医療従事者のためのAIDS/HIV感染症の常識. P30-34 **歯科学研究所インプラント部会雑誌** 2017年2月

宇佐美雄司. HIV感染症. 知りたいことがすぐわかる高齢者歯科医療. **永末書店** in press

宇佐美雄司. 院内感染対策と医療曝露. 知りたいことがすぐわかる高齢者歯科医療. **永末書店** in press

吉野宗宏: 後天性免疫不全症候群. **薬学生・薬剤師レジデントのための感染症学・抗菌薬治療テキスト**. 249-258, 2015.

小島賢一: わが国のHIV/AIDSカウンセリングに関する研究上の課題2. **日本エイズ学会誌**. 2016.

小松賢亮、小島賢一. HIV感染者のメンタルヘルスー近年の研究動向と心理的支援のエッセンスー. **日本エイズ学会誌**. 第18巻3号:183-195, 2016.

鈴木清澄、上原由紀、内藤俊夫. 一般内科におけるHIV感染症診療. **内科**. 16(5):743-746, 2015.

内藤俊夫. HIV感染症の早期発見. **日本医事新報**. 2016;4836:1.

柳澤如樹、安藤稔. HIV感染とCKD. **HIV感染症とAIDS治療**. 6:12-18, 2015.

安藤稔. HIV感染患者におけるCKDと透析療法：現状と方向性. **医薬の門**. 56(5)：224-227, 2016